Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study
NCT ID: NCT05574894
Last Updated: 2023-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
692 participants
INTERVENTIONAL
2021-01-01
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Infertile patients aged 38-46 years old were recruited for study if they fulfill the inclusion criteria and do not have the exclusion criteria.
Treatment group: Women received growth hormone (GH) supplement during antagonist protocol for ovarian stimulation.
Control group: Women received antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts per stimulation cycle and per testing cycle.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
NCT05447208
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A
NCT04414748
Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol
NCT04989348
Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality
NCT03966339
Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles
NCT02908438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GH group
Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
Growth hormone
Growth hormone is supplemented during the ovarian stimulation till the day of trigger
GnRH antagonist
GnRH antagonist protocol for ovarian stimulation
Control group
No Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
GnRH antagonist
GnRH antagonist protocol for ovarian stimulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Growth hormone
Growth hormone is supplemented during the ovarian stimulation till the day of trigger
GnRH antagonist
GnRH antagonist protocol for ovarian stimulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex);
* Untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;
* Women who received other supplement drugs during ovarian stimulation
38 Years
46 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ShangHai Ji Ai Genetics & IVF Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoxi Sun, PhD
Role: STUDY_DIRECTOR
Shanghai JIAI Genetics and IVF Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai JIAI Genetics and IVF Institute
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sui Y, Xiao M, Fu J, Li L, Xu Y, Lei C, Sun X. Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy. J Ovarian Res. 2023 Oct 19;16(1):204. doi: 10.1186/s13048-023-01279-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JIAI E2022-022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.